Candorium Free Members
Join Candorium to access the full article and more
Free Member Benefits:
✔
Comment & Reply✔
Newsletter Access✔
Follow Authors✔
Share via SMS Go Back
Pfizer acquires migraine-drug maker Biohaven for $11.6B
By Yashasvini Razdan - May 10, 2022, 07:26 PM ET
Last Updated - Feb 26, 2024, 03:21 PM EST
Biohaven makes Nurtec ODT, a dual-acting migraine therapy for adults
Pfizer Inc. (NYSE: PFE) announced that it has entered into a definitive agreement to acquire Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) for $11.6 billion in cash.
Biohaven shares soared 68.4%, while Pfizer shares rose more than 1.7%.
Sponsored
Pfizer will acquire all outstanding shares of Biohaven it does not already own for $148.50 per share in cash, a 78.6% premium to Monday's closing price.
Pfizer had invested $350 million, at $173 a share, to acquire a 2.6% stake in Biohaven in November 2021.
Migraine drug market
Biohaven is the maker of Nurtec ODT, a dual-acting migraine therapy approved for both acute treatment and episodic prevention of migraine in adults.
Nurtec brought in sales of $462.5 million in 2021. Pfizer said that Biohaven's migraine drugs could top $6 billion in annual sales at their peak.
Biohaven forecasted Nurtec sales of $825 million to $900 million in 2022.
Pfizer intends to make Biohaven's non-migraine drugs into a new publicly-traded company. Biohaven’s existing shareholders will receive 0.5 shares of the new company for each share of Biohaven stock they currently own.
Source - Pfizer
Read more:
Sponsored
Read More from Market Analysis
Read More from Investing
Popular News
Latest News
